P8A:SGX
Cordlife Group Ltd
SGD 0.12
0.00%
(0.00) 1H
12 Okt, 9:49:20 PG GMT+8 · SGD
search
Semua simbol
| Simbol | Harga | Perubahan | % Perubahan |
|---|
insights_autoMenjana cerapan popular untuk P8A...
Permodalan Pasaran
32.37J
Purata volum
1.32K
Volum
0.00
tgi 52 mgu
SGD 0.26
rdh 52 mgu
SGD 0.10
EPS
-SGD 0.04
Syer tertunggak
267.53J
Bilangan pekerja
111
Permodalan Pasaran
32.37J
Purata volum
1.32K
Volum
0.00
tgi 52 mgu
SGD 0.26
rdh 52 mgu
SGD 0.10
EPS
-SGD 0.04
Syer tertunggak
267.53J
Bilangan pekerja
111
Cerita berita
Daripada sumber web dan rakan kongsi berita
Astro Awani
·
18 jam lalu
S&P 500: Wall Street market update | 15 October 2026
Invezz
·
3 hari lalu
Dow Jones dibuka 190 mata lebih tinggi, pelabur memerhati pendapatan bank dan inflasi
Invezz
·
3 hari lalu
Dow naik 198 mata, saham AS bercampur menjelang keputusan pendapatan
Invezz
·
2 hari lalu
Dow ditutup 170 mata lebih rendah ketika penjualan saham cip berterusan
Profil
Cordlife Group Limited, is a consumer health company incorporated in May 2001 and a provider of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
Cordlife Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six markets including Singapore, Hong Kong, India, Indonesia, and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
Cordlife's stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia were accredited by AABB until 2024 when its accreditation was withdrawn.
In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes. Wikipedia
Perihal Cordlife Group Ltd